Observational studyInternational journal of chronic obstructive pulmonary disease2019
Determinants of healthcare utilization and costs in COPD patients: first longitudinal results from the German COPD cohort COSYCONET.
Observational study in International journal of chronic obstructive pulmonary disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01245933 (Impact of Systemic Manifestations/Comorbidities on Clinical State, Prognosis and Utilisation of Health Care Resources in Patients With COPD), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of Systemic Manifestations/Comorbidities on Clinical State, Prognosis and Utilisation of Health Care Resources in Patients With COPD
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Literature Review of the Humanistic, Economic, Sociodemographic, and Environmental Burden Associated with Severe COPD.International journal of chronic obstructive pulmonary disease · 2025Pooled it
- Reliability, Validity, and Responsiveness of the DEG, a Three-Item Dyspnea Measure.Journal of general internal medicine · 2022Trial
- The Societal and Economic Burden of COPD in Saudi Arabia.Global journal on quality and safety in healthcare · 2026Article
- Loneliness in Chronic Obstructive Pulmonary Disease: A Multidimensional Determinant of Clinical Outcomes and Disease Management.Journal of clinical medicine · 2026Review
- Study Design and Rationale for The Breathe Easier With Tadalafil Therapy for Exercise-Related Dyspnea in COPD-PH (BETTER COPD-PH).Pulmonary circulation · 2025Article
- [TELEMEdical moNiTORing for COPD patients (Telementor COPD): Study protocol of a multicentre, randomised, controlled study].Pneumologie (Stuttgart, Germany) · 2025Article
- Clinical and Economic Burden of COPD in Patients on Inhaled Triple Therapy in Germany - A Retrospective Claims Data Analysis.International journal of chronic obstructive pulmonary disease · 2025Article
- Statins did not reduce the frequency of exacerbations in individuals with COPD and cardiovascular comorbidities in the COSYCONET cohort.Respiratory research · 2024Observational
- Machine learning approaches for practical predicting outpatient near-future AECOPD based on nationwide electronic medical records.iScience · 2024Article
- Insomnia in chronic obstructive pulmonary disease and associations with healthcare utilization and costs.Respiratory research · 2023Article
- Comparison of BODE and ADO Indices in Predicting COPD-Related Medical Costs.Medicina (Kaunas, Lithuania) · 2023Article
- [What have we learned from the German COPD cohort COSYCONET and where do we go from here?]Pneumologie (Stuttgart, Germany) · 2023Article
- Patient experience with chronic obstructive pulmonary disease: a nationally representative demonstration study on quality and cost of healthcare services.Frontiers in public health · 2023Article
- Extracorporeal Artificial Lungs: Co-Creating Future Technology - A Qualitative Analysis.Medical devices (Auckland, N.Z.) · 2023Article
- Comparation of predictive value of CAT and change in CAT in the short term for future exacerbation of chronic obstructive pulmonary disease.Annals of medicine · 2022Article
- Home based pulmonary tele-rehabilitation under telemedicine system for COPD: a cohort study.BMC pulmonary medicine · 2022Article
- Basic Determinants of Disease Knowledge in COPD Patients: Results from COSYCONET.Patient preference and adherence · 2022Article
- Muscle mass and function are related to respiratory function in chronic obstructive pulmonary disease.Medical journal of the Islamic Republic of Iran · 2021Article
- CODEXS: A New Multidimensional Index to Better Predict Frequent COPD Exacerbators with Inclusion of Depression Score.International journal of chronic obstructive pulmonary disease · 2020Article
- Direct and indirect costs of COPD progression and its comorbidities in a structured disease management program: results from the LQ-DMP study.Respiratory research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In light of overall increasing healthcare expenditures, it is mandatory to study determinants of future costs in chronic diseases. This study reports the first longitudinal results on healthcare utilization and associated costs from the German chronic obstructive pulmonary disease (COPD) cohort COSYCONET. Material and methods: Based on self-reported data of 1904 patients with COPD who attended the baseline and 18-month follow-up visits, direct costs were calculated for the 12 months preceding both examinations. Direct costs at follow-up were regressed on baseline disease severity and other co-variables to identify determinants of future costs. Change score models were developed to identify predictors of cost increases over 18 months. As possible predictors, models included GOLD grade, age, sex, education, smoking status, body mass index, comorbidity, years since COPD diagnosis, presence of symptoms, and exacerbation history. Results: Inflation-adjusted mean annual direct costs increased by 5% (n.s., €6,739 to €7,091) between the two visits. Annual future costs were significantly higher in baseline GOLD grades 2, 3, and 4 (factors 1.24, 95%-confidence interval [1.07-1.43], 1.27 [1.09-1.48], 1.57 [1.27-1.93]). A history of moderate or severe exacerbations within 12 months, a comorbidity count >3, and the presence of dyspnea and underweight were significant predictors of cost increase (estimates ranging between + €887 and + €3,679, all Conclusions: Higher GOLD grade, comorbidity burden, dyspnea and moderate or severe exacerbations were determinants of elevated future costs and cost increases in COPD. In addition we identified underweight as independent risk factor for an increase in direct healthcare costs over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.